uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences. (farmakometri)
Daiichi Sankyo Pharma Dev, Edison, NJ USA..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Pharmacy, Department of Pharmaceutical Biosciences.
2015 (English)In: Journal of clinical pharmacology, ISSN 0091-2700, E-ISSN 1552-4604, Vol. 55, no 11, 1268-1279 p.Article in journal (Refereed) Published
Abstract [en]

A model characterizing the population pharmacokinetics (PK) of edoxaban and its major metabolite, M4, following a single oral dose of 15mg administered to subjects with varying kidney function was developed. Thirty-two subjects contributed with edoxaban plasma, edoxaban urine, and M4 plasma concentrations. Edoxaban urine concentrations allowed estimation of renal clearance, and high contribution of renal to total clearance enabled estimation of absolute oral bioavailability. A 2-compartment model with delayed absorption and elimination parameterized as renal clearance linearly related to creatinine clearance (CLcr) and nonrenal clearance forming M4 described edoxaban PK. The PK of M4 was described with a 1-compartment model. For a typical subject (70kg; CLcr, 100mL/min) bioavailability, clearance, and central and peripheral volume of distribution for edoxaban was estimated to 72.3%, 21.0 L/h, 95.4 L, and 54.3 L, respectively. For both edoxaban and M4, the model predicted systemic exposure to increase 57.0%, 35.0%, and 11.6% in a subject having CLcr of 30, 50, and 80mL/min, respectively, compared with a subject having a CLcr of 100mL/min. Concentration ratios (M4 over edoxaban) were predicted to vary with time after dose, but with minor influence of kidney function and body weight. Results were in agreement with previous analyses.

Place, publisher, year, edition, pages
2015. Vol. 55, no 11, 1268-1279 p.
Keyword [en]
edoxaban, metabolite, NONMEM, renal impairment, pharmacokinetic
National Category
Pharmaceutical Sciences
Identifiers
URN: urn:nbn:se:uu:diva-265800DOI: 10.1002/jcph.541ISI: 000362376200010PubMedID: 25966665OAI: oai:DiVA.org:uu-265800DiVA: diva2:866742
Available from: 2015-11-03 Created: 2015-11-03 Last updated: 2017-12-01

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Jönsson, SivSimonsson, Ulrika S. H.Karlsson, Mats O.

Search in DiVA

By author/editor
Jönsson, SivSimonsson, Ulrika S. H.Karlsson, Mats O.
By organisation
Department of Pharmaceutical Biosciences
In the same journal
Journal of clinical pharmacology
Pharmaceutical Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 487 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf